Kriya Therapeutics is a biopharmaceutical company focused on developing innovative gene therapies aimed at addressing significant unmet medical needs across various therapeutic areas, including neurology and ophthalmology. Their approach involves targeting validated biological pathways with the potential to deliver transformative benefits to patients suffering from conditions such as trigeminal neuralgia, focal epilepsy, and thyroid eye disease. Kriya's investigational therapies, such as KRIYA-748 and KRIYA-382, utilize adeno-associated virus (AAV) technology to express engineered ion channels that can modulate neuronal activity in response to an FDA-approved small molecule, varenicline. This targeted delivery system aims to provide long-lasting pain relief and seizure control while minimizing the need for ongoing medication or invasive surgical procedures.

Kriya's research and development strategy emphasizes a comprehensive and scalable approach to gene therapy, integrating advanced techniques in protein engineering, vector genome design, and capsid selection. By leveraging computational biology and large-scale Good Manufacturing Practice (GMP) manufacturing capabilities, Kriya aims to streamline the transition from discovery to clinical application. Their rigorous development process includes optimizing manufacturability and biological activity, ensuring that their gene therapy candidates can be produced consistently and effectively for clinical trials. This innovative framework positions Kriya Therapeutics to potentially revolutionize the accessibility and effectiveness of gene therapies for a wide range of diseases affecting millions globally.

United States

Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.

Endocrine System Diseases

Eye Diseases

Genetic Diseases

Metabolic Diseases

Nervous System Diseases

Kriya Therapeutics

Diabetic retinopathy

Geographic atrophy

Uveitis

Kriya Drug #1

Biologics

Gene Therapy

Epilepsy

Trigeminal Neuralgia

Kriya Drug #2

Diabetes

Glycogen Storage Disease

Kriya Drug #3

Redwood City, California, United States of America

California - North

California

Adeno-associated viral vector (AAV)

Bioinformatics

Cell Therapies

Therapeutic

Kriya Therapeutics

Company Details